Background: Only patients with wild-type (WT) KRAS tumors benefit from anti-epidermal growth factor receptor (EGFR) monoclonal antibodies (Mabs) in metastatic colorectal cancer (mCRC). Pyrosequencing is now widely used for the determination of KRAS mutation burden and a conservative cut-off point of 10% has been defined. Up until now, the impact of low-frequency KRAS mutations (<10%) on the response to anti-EGFR Mabs has yet to be evaluated.
introduction
Worldwide, 1 million patients are diagnosed annually with colorectal cancer (CRC), and 50% of them will eventually develop metastatic disease [1] . Before the initial use of monoclonal antibody (Mab), combinations of fluorouracil (FU), leucovorin and oxaliplatin (FOLFOX) or irinotecan (FOLFIRI) were considered as standard chemotherapy for metastatic CRC (mCRC). Over recent decades, clinical trials have shown the benefit of adding anti-EGFR (epidermal growth factor receptor) or anti-VEGF (vascular endothelial growth factor) Mabs to chemotherapy in the treatment of mCRC [2] [3] [4] . As a result, anti-EGFR Mabs, cetuximab and panitumumab, are now used as standard treatment in cases of advanced colorectal cancer, in combination with cytotoxic chemotherapy in first-, second-and third-line chemotherapy [3] [4] [5] . The anti-EGFR Mabs block downstream activation of the EGFR pathway, which is composed of the RAS-RAF-MAPK and PI3K-PTEN-AKT axes. It is now a well-established fact that only patients with wild-type (WT) KRAS tumors may benefit from treatment with an anti-EGFR agent. Conversely, patients with tumors harboring a KRAS mutation show a response rate <5% [5] [6] [7] [8] [9] [10] [11] [12] .
Several studies have shown KRAS mutations to be present in ∼35%-43% of mCRC [13, 14] . One may note that in patients without KRAS mutation in tumors who were receiving anti-EGFR as a first-line chemotherapy, both the response rate and median progression-free survival (PFS), 55%-60% and 9-10 months, respectively, were relatively low [3, 5] . Moreover, some patients with WT KRAS tumors did not respond to anti-EGFR treatment [5] [6] [7] [8] [9] [10] [11] [12] . One possible explanation for these observations may consist in the limited sensitivity of conventional sequencing methods in the detection of KRAS mutations; in that case, further investigations aimed at optimizing treatment selection and strategy would be particularly called for.
Up until now, screening and identification of gene mutations in malignant tumors such as those with KRAS status have been routinely carried out by dideoxy DNA sequencing or PCRbased specific or screening techniques. However, direct sequencing for diagnostic use presents several critical disadvantages that have been reported [15] . One of them involves low sensitivity and a lack of objective criteria allowing to distinguish low-signal mutants from non-specific background. It was recently suggested that in order to be reproducibly detected, mutant alleles must represent at least 20% of the signal [16] . The use of more sensitive methods has significantly improved the detection of KRAS mutations and led to more accurate identification of patients resistant to anti-EGFR Mabs [17] . At present, quantification of the mutation rate is a major priority, and the use of quantitative pyrosequencing-based methods has underscored interindividual differences in the mutation burden of colorectal tumors [15] .
Pyrosequencing is a real-time, non-electrophoretic, nucleotide-extension sequencing technique, and it has shown to be efficient in various applications [18] [19] [20] [21] . In pyrosequencing, only when the dispensed nucleotide anneals to the template does primer extension generate a pyrophosphate, which is then chemically modified to generate a secondary reagent leading to photon emission. Photon intensity is proportional to the amounts of incorporated nucleotides, thereby reflecting the actual proportions of a single allele. Pyrosequencing is now routinely used in KRAS mutation detection, and the technical threshold for a positive signal has been set at 10% [15] .
In the present study, we evaluated the clinical impact of considering as positive a KRAS mutant harboring a signal below the 10% threshold. With this in mind, we retrospectively studied the response rates in patients treated by anti-EGFR Mabs and presenting a low KRAS mutant signal.
patients and methods
patients From January 2006 until June 2011, all the consecutive patients with WT KRAS status using direct sequencing and treated by anti-EGFR at Poitiers and Tours University Hospital for a mCRC were included in this study. Patients were treated with an anti-EGFR monoclonal antibody (cetuximab or panitumumab) alone or combined with chemotherapy (5 FU, oxaliplatin and/or irinotecan) regardless of the chemotherapy line. Cetuximab was administered weekly (400 mg/m 2 as an initial dose followed by 250 mg/m 2 ) or every 2 weeks (500 mg/m 2 ). Panitumumab was given every 2 weeks (6 mg/kg). Treatment was continued until progressive disease or toxicity occurred, according to the standard criteria. The clinical response was assessed every 6-8 weeks using the Response Evaluation Criteria In Solid Tumors (RECIST).
determination of KRAS status using pyrosequencing
All tumoral samples were obtained before the beginning of anti-EGFR therapy. All samples contained a minimal proportion of 50% tumor cells (evaluated histologically). Genomic DNA was extracted from paraffinembedded tissues using the DNAeasy Blood and Tissue DNA isolation kit or the QIAamp DNA Mini Kit (Qiagen, Hilden, Germany) according to the manufacturer's instructions. The same extracted DNA was used for the dideoxysequencing method as well as for pyrosequencing. Genotyping of KRAS exon 2 (codons 12 and 13) and exon 3 (codon 61) was carried out by a pyrosequencing method using the PyroMark Q24 and CE-IVD-marked Therascreen® KRAS Pyro® kit (Qiagen). Pyrosequencing analyses were carried out according to the manufacturer's instructions (Qiagen). The results were interpreted using the PyroMark Q24 2.0 software (Qiagen).
Patients with >10% of mutant allele burden were not considered for the study (KRAS mutation). The technique and the 10% threshold defining a KRAS mutation were not modified over time. The cut-off value, discriminating low-frequency KRAS mutations and WT sequence, was assigned at 2.3% of the mutant allele burden. This cut-off was determined by the manufacturer as the limit of detection (LOD) using the KRAS Plugin Report algorithm. Patients were stratified into two groups: WT KRAS (0-2.3% of the mutant allele, KRAS WT) and low-frequency KRAS mutation (2.3%-10% of mutant allele burden, KRAS low MT). Data were reproducible, and all mutations were found and confirmed at least twice with two independent experiments. Each experiment included an unmethylated control-DNA for comparison and background level determination, as well as a known-mutated sample.
Genotyping of BRAF exon 15 was carried out by direct sequencing with capillary electrophoresis using the ABI Prism 3500 analyzer with or without a screening step using HRM (high-resolution melting).
statistical analysis
Follow-up data were updated in December 2011. PFS was defined as the time from the first anti-EGFR administration to either the first objective evidence of disease progression or death from any cause or the date of the last follow-up (if there was no progression). Overall survival (OS) was defined as the time from the diagnosis of metastatic disease to death from any cause or the date of the last follow-up.
Fisher's exact test and the Mann-Whitney test were used for comparison of patient and tumor characteristics. The PFS and OS data were plotted as Kaplan-Meier curves and the differences between the groups categorized by pyrosequencing-identified KRAS statuses were compared by the logrank test. All statistical analyses were carried out with a two-sided significance value of 0.05.
results patient and tumor characteristics
A total of 168 patients treated by anti-EGFR for a mCRC were included in the study. The mean age was 64.3 ± 11.3 years and a majority of patients had synchronous metastases (67.3%). Patients were treated using anti-EGFR in first-line chemotherapy (29.2%), second-line (28.6%), third-line (31.5%) or later (10.7%). Most of the patients had anti-EGFR combined with cytotoxic chemotherapy (92.3%), primarily irinotecan (82.1%). Cetuximab was used in 78.6% and panitumumab in 21.6% of the cases. After anti-EGFR Mabs, 18 patients underwent surgery for their metastatic disease (10.7%).
The median patient follow-up was 26.9 ± 19.6 months. The response rates according to RECIST criteria were 31.5% partial response (PR), 30.9% stabilization and 36.3% progression (two patients were not assessable). The median PFS was 5.7 ± 0.7 months and the median OS was 32.0 ± 3.1 months. Using direct sequencing, the 168 patients were not diagnosed as carrying KRAS mutations. KRAS analyses were carried out in primary tumors (n = 147, 87.5%) or in metastatic disease (n = 21, 12.5%). When using pyrosequencing, 138 tumors were confirmed with regard to KRAS WT status and 30 tumors presented a KRAS mutation, with a signal below the technical threshold and ranging from 2.3% to 10% (KRAS low MT). All in all, pyrosequencing detected 17.9% of the KRAS mutations in patients with KRAS WT using direct sequencing alone (30 tumors among 168). Moreover, the frequency of the individual types of KRAS mutation detected by pyrosequencing did not differ from the KRAS mutations detected using direct sequencing [10] [11] [12] 22] . While patient demographic data showed no significant difference between the two groups (Table 1) , we observed that patients in the KRAS low MT group had received more chemotherapy lines before anti-EGFR treatment (Table 2) . Among tumors in the KRAS low MT group, four of it also presented a BRAF mutation (13.3%). No KRAS mutation in codon 61 was detected. The KRAS low MT group is detailed in Table 3 and the representative pyrosequencing graphs are shown in Figure 1. response rate, progression-free survival and overall survival according to KRAS status
In the cohort study, the response rates were 6.7% versus 37.0% PR, 23.3% versus 32.6% stable disease and 70% versus 29.0% progressive disease (P < 0.01), for KRAS low MT and KRAS WT, respectively (Figure 2 ). Through pyrosequencing, the rate of identification of non-responder patients could be reduced from 36.3% to 29%. Two patients were not assessable in the KRAS WT group. Two patients had KRAS low MT and responded to anti-EGFR at 3 months. One patient had FOLFIRI plus cetuximab after FOLFIRI plus bevacizumab progression and responded to anti-EGFR. Afterwards, this patient benefited from hepatic metastasis treatment with stereotactic body radiation therapy (PFS 36.2 months). The other patient had cetuximab plus irinotecan after irinotecan and oxaliplatin progression and responded at 3 months, but then progressed at 7.6 months.
The PFS was respectively 2.7 ± 0.5 months for KRAS low MT versus 6.0 ± 0.3 months for KRAS WT (P < 0.01) (Figure 3) . OS was not different between the two groups (30.4 ± 1.1 months for KRAS low MT versus 32.6 ± 1.7 months for KRAS WT, P = 0.86).
discussion
In this study, we have shown that patients with tumors harboring KRAS mutations at a ratio <10%, as determined by pyrosequencing, benefit less from anti-EGFR therapy than patients with tumors harboring KRAS WT, in mCRC. Indeed, KRAS mutation is the major predictive factor with regard to anti-EGFR efficacy. Nevertheless, no standardized procedures for KRAS mutation detection have been proposed to date. Up until this time, most of the studies establishing an association between KRAS mutation and lack of response to anti-EGFR Mabs have been carried out by direct sequencing [16] . Several critical disadvantages of direct sequencing for a diagnostic use have already been indicated, such as its low sensitivity and the nonexistence of reliable criteria helping us to distinguish mutant signals from the background. This is particularly important when using DNA isolated from formalin-fixed paraffin-embedded specimens, which contain poorly amplifiable DNA [23] . To increase the sensitivity of direct sequencing, macroscopic isolation of tissues in which cancer cells represent >70% of the area (microdissection) has been recommended [24] . However, not all clinical samples fulfill this criterion. Pyrosequencing is a powerful and sensitive sequencing technology for single nucleotide polymorphisms, since it can accurately quantify the relative amount of each allele [19] , including KRAS mutation status [15, 18, 25] . For our daily practice, within the network of platforms promoted by the French National Cancer Institute (INCa), we have been using this technology since June 2011. As was the case with other researchers, we first used the conservative cutoff of 10% as the lower limit of quantification in our assignment of KRAS mutation status [15, 26] . However, for the CE-IVD-marked Therascreen® KRAS Pyro® kit (Qiagen) a LOD has been defined for some particular mutations on codon 12 of 13 at a pronouncedly lower level (2.3%). The analytical sensitivity of pyrosequencing allows it to efficiently detect KRAS mutations representing a percentage of mutated cells as low as 1% [18, 27] . Therefore, the aim of our study was to correlate the detection of KRAS mutant alleles <10% with regard to the efficacy of anti-EGFR Mabs in mCRC.
Given that direct sequencing harbors only limited sensitivity [15, 26] , our results first showed that by using pyrosequencing instead, we could detect additional KRAS mutation in up to 30 out of 168 cases (17.9%). The presence of subclones harboring KRAS mutations within heterogeneous tumors may explain the low-frequency KRAS mutations. Moreover, four patients with KRAS low MT harbored BRAF mutations. KRAS and BRAF mutations were considered to be mutually exclusive [28] . The existence of BRAF mutations in tumors with KRAS low MT is consistent with the idea that KRAS mutation is present in only a small portion of subclones. Such a low percentage of tumor cells may exert some influence on the detection of KRAS mutations [15, 16] . Studies have demonstrated that tumor heterogeneity is quite common, being found in about 10% of cases and even between adjacent neoplastic areas [29, 30] . Moreover, KRAS mutations detected using pyrosequencing can be below the sensitivity level of dideoxysequencing detection as a consequence of a low percentage of tumour cells in the sample or intratumoral genetic heterogeneity. It is worthwhile to note that sequencing and pyrosequencing were made on the same tumoral sample in our study.
Furthermore, our study clearly demonstrated that in KRAS low MT disease, when compared with KRAS WT, disease progression was higher (70% versus 29.0%). This progression was likewise associated with a weaker response to treatment (6.7% versus 37%) (P < 0.01). This result could be explained by the positive selection of KRAS mutant subclones furthered by the elimination of anti-EGFR-dependent WT tumor cells. PFS was also shorter in patients with KRAS low MT when compared with KRAS WT (2.7 ± 0.5 months versus 6.0 ± 0.3 months, respectively, P < 0.01). Molinari et al. subsequently retrospectively studied a particularly large series of patients in whom KRAS mutations were assessed by MALDITOF MS (matrix-assisted laser desorption/ionization-time-of-flight mass spectrometry), mutant-enriched PCR and engineered mutant-enriched PCR (ME-PCR), which have a sensitivity of 20%, 10%, 0.1% and 0.1%, respectively, showing that the use of ME-PCRs increases the rate of identification of non-responders [31] . Nevertheless, these results using highly sensitive methods were assessed only on 13 patients with additional KRAS mutations.
As observed for direct sequencing diagnosed patients, the OS rate did not significantly differ between the two groups. Moreover, the high response rate and high PFS in patient KRAS WT in second-or third-line chemotherapy, when compared with those reported in the literature [12, [32] [33] [34] [35] [36] , could be explained by exclusion of patients with KRAS low MT. Moreover, high OS, exceeding 30 months, was probably explained by a selection bias of patients who were likely to benefit from anti-EGFR Mabs in second-or third-line chemotherapy. In randomized trials in first-or second-line chemotherapy, patients with tumors harboring KRAS mutations and receiving anti-EGFR Mabs have a response rate of 13%-40% and the median PFS ranged from 5 to 7.6 months [3, 5, 37] . Accordingly, in retrospective series, the response rate was 0%-16.4% and the median PFS ranged from 2 to 3.1 months in first-, second-or third-line chemotherapy with anti-EGFR Mabs [12, [32] [33] [34] [35] [36] . All of these observations were similar to those obtained in our study for KRAS low MT, a finding which suggested that inefficient anti-EGFR treatment was to be observed regardless of the frequency of KRAS-mutated cells within the tumor. Surprisingly, 2 of the 30 patients with KRAS low MT showed PR to anti-EGFR. In these patients, the mutation status was established only for the primary tumor, while the metastases Response rate according to KRAS status. Response rates were 6.7% versus 37.0% partial response, 23.3% versus 32.6% stable disease and 70% versus 29.0% progressive disease (P < 0.01), for KRAS low MT and KRAS WT, respectively. Two patients were not assessable in the KRAS WT group. were not available for examination and may have had a different KRAS status [38] . In another recent study, Santini et al. likewise observed PRs in patients with low-frequency KRAS mutations [26] . More generally speaking, our results suggest that patients are likely to benefit from the development of sensitive methodologies for analysis of predictive molecular markers such as KRAS status. It should nonetheless be noted that in our study, the cohort of patients was heterogeneous according to the chemotherapy regimen, which means that our results still require confirmation by means of a prospective assessment of KRAS status. PFS data are heterogeneous in our study due to the various chemotherapy regimens used and the fact that patients were in first-, second-and third-line chemotherapy. Nevertheless, patient's demographic data and chemotherapy regimen were not significantly different between the two groups. We only observed that patients in the KRAS low MT group had received more chemotherapy lines before anti-EGFR treatment than those in the KRAS WT group. Moreover, PFS data in the KRAS low MT group, when compared with the literature, were similar to those pertaining to patients with tumors harbouring KRAS mutations. In addition, there is a major significant difference in the response rate between the two groups. An evaluation of KRAS mutant alleles' frequency during anti-EGFR therapy would also help during patient follow-up to explain progression during anti-EGFR therapy; more specifically, low-frequency KRAS mutation may elucidate anti-EGFR rechallenge [39] . Moreover, a recent study described the occurrence of EGFR mutation during anti-EGFR therapies [40] . And in addition, a minor subclone with KRAS mutation 'hidden' within primary tumors might be positively selected to induce local recurrence and metastasis. Comparison of the percentage of mutant alleles in metastasis and the primary tumors would be particularly useful. Concordance of KRAS and BRAF status between primary tumors and metastasis is apparently the rule in CRC, with heterogeneity <10% [38, 41] . Nevertheless, this feature may differ with regard to low MT KRAS. Finally, our data support the idea that in light of lowfrequency KRAS mutation, it might well be interesting to reconsider published results, the NORDIC trial being just one example [42] .
As a conclusion, we have shown that patients harbouring KRAS low MT benefit less than others from anti-EGFR therapy. Logically, improved sensitivity of bioassays meant to detect minor mutated clones should enhance the identification of the patients not responding to anti-EGFR therapy. Optimized diagnosis could, in turn, have major consequences in terms of cost-effectiveness by further rationalizing the selection of anti-EGFR therapy. To conclude, health care regulators should be strongly urged to make every effort to harmonize detection methods for KRAS mutations, pyrosequencing being one of the presently available technical options. New and highly sensitive techniques such as microdroplet technology should also be evaluated [43] .
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